{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Increase of QTcF by >60 msec from baseline', 'Based on average QTcF value of triplicate electrocardiograms (ECGs) to include', 'manual over-read. For example, if an ECG demonstrates a prolonged QT interval,', 'obtain 2 additional ECGs over a brief period (e.g., within approximately 10 minutes', 'of the abnormal ECG, if possible, and approximately 10 minutes apart from each', 'other), and then use the averaged QTc values of the 3 ECGs to determine whether', 'the participants should have study treatment(s) withheld. The QTc should be based', 'on single or averaged QTc values of triplicate electrocardiograms obtained over a', 'brief (e.g., 5-10 minute) recording period.', \"The QT interval should be corrected for heart rate by Fridericia's formula (QTcF).\", '8.2.4.', 'Left Ventricular Ejection Fraction (LVEF) Stopping Criteria', 'Echocardiography must be performed at Screening. If an ECHO is done at any point', 'during the study, the following stopping criteria are to be employed. Participants who', 'have an asymptomatic absolute decrease of > 10% in LVEF and the ejection fraction is', \"below the institution's lower limit of normal (LLN) should temporarily discontinue study\", 'treatment and have a repeat evaluation of LVEF within 1 week. Echocardiogram', '(ECHO) should be repeated every 1 to 2 weeks for 4 weeks or until LVEF recovery to', 'above institutional LLN and within 10% of baseline.', 'If the LVEF recovers (defined as institutional LLN and absolute decrease', '<10% compared with baseline) at any time during the next 4 weeks, after', 'consultation with and approval from the GSK medical monitor, the participant', 'may be restarted on GSK2857916 at a reduced dose. For such participants,', 'monitoring of LVEF will be performed 2 and 4 weeks after re-challenge, then', 'every 4 weeks for a total of 16 weeks.', 'If repeat LVEF does not recover within 4 weeks, treatment must be permanently', 'discontinued. Ejection fraction must be monitored every 4 weeks for a total of', '16 weeks or until resolution (whichever occurs first).', 'Participants with Grade 3 or 4 (symptomatic) left ventricular systolic dysfunction must', 'interrupt treatment with GSK2857916. Ejection fraction must be monitored every 4', 'weeks for a total of 16 weeks or until resolution. If recovery occurs (LVEF', '>', 'institutional LLN and symptom resolution) within 4 weeks, then treatment with', 'GSK2857916 may be restarted at a reduced dose in consultation with the medical', 'monitor.', '8.2.5.', 'Corneal Event Stopping Criteria', 'All GSK2857916 dose modifications and stopping criteria are to be based on the GSK', 'Scale for GSK2857916 Corneal Events (Appendix 9). Corneal events will be graded', 'according to both CTCAE criteria for eye disorders (see Section 9.2) and the guidelines', 'provided in Appendix 9. The treating physician or ophthalmologist (or optometrist, if an', 'ophthalmologist is not available) must discuss the participants who develop a Grade 4', 'corneal event according to the GSK scale with the GSK Medical Monitor or a GSK', 'ophthalmologist to determine whether the participant can be allowed to restart treatment', '69']['2017N330177_04', 'CONFIDENTIAL', '205678', 'with GSK2857916 or whether GSK2857916 should be permanently discontinued. The', 'decision will be documented in study files, together with individual assessment of risk-', 'benefit. For details on re-start guidance (Table 13).', '8.2.6.', 'Infusion-Related Reaction Management and Stopping Criteria', 'Premedication is not required prior to infusion unless deemed medically appropriate by', 'the investigator following evaluation of infusion related reactions. Premedication should', 'be considered in any participant who experienced an infusion related reaction at first or', 'any subsequent infusion with GSK2857916.', 'IRRs should be managed by guidelines provided in Table 11. A participant that', 'experiences a Grade 4 IRR should be permanently withdrawn from the study.', '8.2.7.', 'Allergic and Anaphylactic Reaction Stopping Criteria', 'All participants will be monitored carefully for evidence of allergic response. A', 'participant that exhibits signs or symptoms of severe hypersensitivity or anaphylaxis will', 'receive appropriate medical treatment and be permanently withdrawn from the study', 'treatment.', '8.3.', 'Withdrawal from the Study', 'A participant may withdraw from the study at any time at his/her own request,', 'or may be withdrawn at any time at the discretion of the investigator for safety,', 'behavioral, compliance or administrative reasons.', 'If the participant withdraws consent for disclosure of future information, the', 'sponsor may retain and continue to use any data collected before such a', 'withdrawal of consent.', 'If a participant withdraws from the study, he/she may request destruction of any', 'samples taken and not tested, and the investigator must document this in the site', 'study records.', 'Refer to the SOA for data to be collected at the time of study discontinuation', 'follow-up and for any further evaluations that need to be completed.', '8.4.', 'Lost to Follow Up', 'The following actions must be taken in relation to a participant who fails to attend the', 'clinic for a required study visit:', 'The site must attempt to contact the participant and re-schedule the missed visit', 'as soon as possible.', 'The site must counsel the participant on the importance of maintaining the', 'assigned visit schedule and ascertain whether or not the participant wishes to', 'continue or if the investigator believes that the participant should continue in the', 'study.', '70']\n\n###\n\n", "completion": "END"}